UICC partner updates
UICC is proud to work with a variety of partners who share its mission to reduce the global cancer burden. To learn more about how UICC works with partners contact partnerships@uicc.org.
New partners
Servier
The Servier Group is dedicated to advancing therapeutic progress to meet patient needs.
Servier has joined as a Benefactor partner supporting both UICC’s priority mission activities and the Access to Oncology Medicines (ATOM) Coalition.
Regeneron Pharmaceuticals
Regeneron’s mission is to use the power of science to bring new medicines to patients, over and over again.
Regeneron have joined as a Champion partner supporting UICC’s priority mission activities.
Partner updates
2024 Wrap Up
UICC continued in 2024 to foster deep relationships with its partners through dialogue and collaboration at high-profile events, such as the World Health Assembly (WHA) in Geneva, the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, and the European Society for Medical Oncology (ESMO) Congress in Barcelona,
In September, UICC's flagship World Cancer Congress in Geneva served as a focal point for partner engagement. Several UICC partners played prominent roles as event sponsors, speakers, and participants, demonstrating their commitment to the global cancer agenda. The World Cancer Congress provided a high-visibility platform for partners to showcase their contributions, build alliances, and participate in key policy and equity discussions.
UICC partners’ sponsorship of and active participation in key programmes and events such as the World Cancer Congress underscores a shared commitment to reducing the global cancer burden. The opportunity for partners to engage directly with UICC's CEO, President, President-elect, and board members has enabled UICC and its parters to forge stronger ties and lay the groundwork for effective collaborations in 2025 and beyond.
World Health Assembly and ASCO
19-27 May will see the World Health Assembly (WHA) once again take place in Geneva. Held annually, the WHA provides a unique platform to discuss critical health issues, share insights, and collaborate on strategies to relieve the cancer burden. UICC looks forward to warmly welcoming its partners to Geneva, where they can join in meaningful dialogues, forge new alliances and strengthen existing partnerships to advance the global health agenda.
Following the WHA, the ASCO General Meeting in Chicago is another significant opportunity for UICC to connect with both current and future partners in the oncology community. A dedicated team from UICC will travel to Chicago to participate in this premier event, which brings together oncologists, researchers, and healthcare professionals from around the world. This gathering is an essential part of UICC's efforts to foster partnerships and drive progress in reducing the global burden of cancer.
UICC and Bristol Myers Squibb
Bristol Myers Squibb has partnered with UICC since 2008, creating a shared value partnership. Through this partnership, Bristol Myers Squibb supports the Access to Oncology Medicines (ATOM) Coalition, UICC's mission activities, the World Cancer Congress, and World Cancer Leaders Summit.
Notably, for over ten years, the global Bristol Myers Squibb workforce has come together to demonstrate its long-standing commitment to cancer research through the C2C4C charity bike rides: Country 2 Country 4 Cancer (Europe), Coast 2 Coast 4 Cancer (United States), and Continent 2 Continent 4 Cancer (Japan and Latin America).
The tradition began in 2014 when a group of oncology employees in the US were compelled to do more for those impacted by cancer. Those efforts expanded to Europe in 2016, Japan in 2021 and Latin America in 2022.
In the US, across Europe, in Japan and in Latin America, the ride includes hundreds of employees representing more than 30 nations, who volunteer their time to train, fundraise, and participate in these epic bike rides, where their miles make more memories for cancer patients and their loved ones. Since its inception, more than $14 million USD has been donated to advance cancer research worldwide. In Europe and Latin America, the funds raised go to support UICC members in the region.
Our partners' expertise and engagement are fundamental to driving long-term and measurable changes in cancer control.
Our partners
Becoming a UICC partner is a valuable opportunity for an organisation to expand its global impact on cancer control and to address Sustainable Development Goal 3, to “ensure healthy lives and promote well-being for all at all ages”.
Become a partner
Last update
Monday 17 February 2025